Amgen announced positive Phase 3 trial results for dazodalibep, showing significant improvements in systemic disease activity and patient-reported symptoms in Sjögren's disease, a condition with no FDA-approved treatments. The OASIZ-301 study demonstrated that dazodalibep reduced disease activity as early as Week 4 and sustained through Week 48, also improving dryness symptoms. These findings support dazodalibep as a potential first-in-class treatment, with further Phase 3 studies ongoing to confirm its benefits and safety profile.
Amgen shares trade at USD 459.98 on Pluang as of Nov 11, 2026 20:11 WIB, down 1.13% for the day. The stock holds a market cap of $251.65 billion and a dividend yield of 2.17%. Pluang investors show strong interest, with 100% buy orders recorded at this time.
Amgen and Regeneron both pay dividends but cater to different retiree needs: Amgen provides a higher, steadily increasing dividend yield of about 2.16%, suitable for retirees needing income now. Regeneron offers a smaller dividend yield of 0.41% but ...
New independent analyses presented by Amgen show that Repatha (evolocumab) is highly cost-effective for high-risk patients without prior heart attack or stroke, reducing major cardiovascular events by up to 29%. The VESALIUS-CV trial data demonstrate...
Amgen has increased its quarterly dividend from $0.28 in 2011 to $2.52 in 2026, representing an 800% growth over 15 years. The company’s dividend raises have slowed recently but remain supported by strong cash flow and reduced share count. With divid...
